- Home
- PLRX vs RGR Comparison
PLRX vs RGR Comparison
Compare PLRX & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | RGR |
|---|---|---|
| Founded | 2015 | 1949 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ordnance And Accessories |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 521.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PLRX | RGR |
|---|---|---|
| Price | $1.22 | $31.83 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $3.79 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 468.4K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 2.19% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $540,770,000.00 |
| Revenue This Year | N/A | $0.73 |
| Revenue Next Year | N/A | $2.27 |
| P/E Ratio | ★ N/A | $202.34 |
| Revenue Growth | N/A | ★ 3.90 |
| 52 Week Low | $1.10 | $28.33 |
| 52 Week High | $14.30 | $48.21 |
Technical Indicators
Market Signals| Indicator | PLRX | RGR |
|---|---|---|
| Relative Strength Index (RSI) | 34.56 | 43.42 |
| Support Level | $1.19 | $30.93 |
| Resistance Level | $1.30 | $33.72 |
| Average True Range (ATR) | 0.11 | 1.26 |
| MACD | -0.01 | 0.35 |
| Stochastic Oscillator | 12.50 | 53.41 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.